Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Table 1 Comparison of three-generation EGFR-TKIs

Representative drugs	Types of inhibitors	Targets of EGFR	ORR (%)	PFS (months)	OS (months)	Ref
First-generation EGFR- TKIs
Gefitinib	Reversible	Ex19del, L858R	67–74	9.2–11.9	30.5–38.8	[5, 6]
Erlotinib	Reversible	Ex19del, L858R	64	9.7–13.1	19.3	[34, 35]
Icotinib	Reversible	Ex19del, L858R	/	11.2	30.5	[36, 37]
Second-generation EGFR-TKIs
Afatinib	Irreversible	Ex19del, L858R	70	11.0–13.6	19.6–27.6* 30.7–33.3*	[7, 39, 41, 42]
Dacomitinib	Irreversible	Ex19del, L858R	75	14.7	34.1	[8, 44]
Third-generation EGFR- TKIs
Osimertinib	Irreversible	Ex19del, L858R T790M	80	18.9	38.6	[22, 46]
Aumolertinib	Irreversible	Ex19del, L858R T790M	74	19.3	NR	[47]
Furmonertinib	Irreversible	Ex19del, L858R T790M	74	20.8	NR	[48, 243]
Lazertinib	Irreversible	Ex19del, L858R T790M	55	11.1	NR	[244, 245]

EGFR-TKIs epidermal growth factor receptor tyrosine kinase inhibitors, wt wild type, ORR objective response rate, PFS progression-free survival, OS overall survival, NR not reached
*The upper data was derived from patients with L858R and the lower data was derived from patients with Ex19del. All exhibited data were derived from clinical trials in which drug as monotherapy in the first-line setting

ISSN: 1756-8722